Symbicort is a combination inhaler used to control asthma and to maintain airflow in people with chronic obstructive ...

namely maintenance treatment for asthma and chronic obstructive pulmonary disease (COPD). Symbicort brought in worldwide sales of $2.7 billion last year, with $1.1 billion of that coming from the ...

a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched ...

Opens in a new tab or window There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease ...

They provided evidence to guide treatment decisions for COPD patients. Study: Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease ...

"Previous findings have shown the beneficial effects of combination budesonide and formoterol, i.e. Symbicort, therapy in significantly reducing COPD exacerbations", explained Professor Peter ...

Symbicort was first FDA-approved in 2006 as a treatment for asthma, followed by an extension to its label covering COPD in 2009 ... in a single inhaler. A Viatris spokesperson said: "Viatris ...

More information: William B Feldman et al, Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study, BMJ (2024).

Purpose. Special considerations in the selection of medication inhaler devices for elderly patients with chronic obstructive pulmonary disease (COPD) in the ambulatory care setting are reviewed.